MYL

Mylan Inc. Press Releases

$45.61
*  
0.12
0.26%
Get MYL Alerts
*Delayed - data as of Oct. 1, 2014 9:36 ET  -  Find a broker to begin trading MYL now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
View:    MYL Real Time
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save stocks for next time
Viewing
Filtered By
Ordered By

Mylan Commences Phase III Clinical Trials for its Generic Version of Advair Diskus® and Insulin Analog to Lantus®
9/16/2014 7:30:00 AM - PR Newswire

Mylan Signs Agreement with Gilead to Accelerate Access to Hepatitis C Treatments, Sovaldi® (Sofosbuvir) and Single Tablet Regimen of Ledipasvir/Sofosbuvir, in Developing Countries
9/15/2014 6:30:00 AM - PR Newswire

Mylan to Acquire U.S. Rights to Arixtra® (fondaparinux sodium) Injection from Aspen
9/10/2014 7:00:00 AM - PR Newswire

Court Grants Summary Judgment in Favor of Mylan and FDA Related to Generic Precedex™
9/8/2014 7:00:00 AM - PR Newswire

Mylan Launches Generic Boniva® Injection
9/5/2014 7:30:00 AM - PR Newswire

Mylan's ANDA for Three Times Per Week Generic Copaxone® 40 mg/mL Accepted for Filing by FDA
8/28/2014 11:21:00 AM - PR Newswire

Ready2Go™ Draft Winners Join Pro Football MVP Adrian Peterson in Educational Video About Anaphylaxis Preparedness
8/25/2014 8:01:00 AM - PR Newswire

Mylan Launches First Generic Klor-Con® Extended-Release Tablets
8/22/2014 7:30:00 AM - PR Newswire

Mylan Launches Generic Precedex™ Injection - Another Key Product Approval
8/19/2014 11:42:00 AM - PR Newswire

Mylan Launches Generic Xeloda® Tablets
8/11/2014 7:30:00 AM - PR Newswire

Mylan Reports Second Quarter 2014 Adjusted Diluted EPS of $0.69, In Line With Guidance
8/7/2014 6:30:00 AM - PR Newswire

Mylan Wins Motion for Temporary Restraining Order Against Apotex for Authorized Generic of Paxil® CR
7/23/2014 7:00:00 AM - PR Newswire

Mylan Wins Motion to Enjoin GlaxoSmithKline from Providing Paroxetine CR to Apotex; Apotex Can No Longer Supply Authorized Generic Product
7/17/2014 7:00:00 AM - PR Newswire

Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction
7/14/2014 6:30:00 AM - PR Newswire

Mylan Launches Generic Micardis® Tablets
7/8/2014 7:30:00 AM - PR Newswire